Penserra Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Penserra Capital Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,614	Closed	-$7K	–	1348
2022 Q2	$7K	Buy	3,614 +1,015	+39%	+$7.04K	﹤0.01%	1332
2022 Q1	$25K	Sell	2,599 -1,889	-42%	-$16.9K	﹤0.01%	1205
2021 Q4	$44K	Buy	+4,488	New	+$44.6K	﹤0.01%	1057

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CGC

Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Penserra Capital Management's GRNA Position: Q3 2022 in Review

Penserra Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2022, closing a stake of 3,614 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in GRNA in Q4 2021 and held it in 3 quarters. The position peaked at $44K in Q4 2021. 57 funds tracked by Wall St. Rank hold GRNA as of Q3 2022.

Penserra Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2022 after selling out during the quarter.
Penserra Capital Management sold 3,614 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2022, an estimated $7K.
Penserra Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q4 2021 and held it in 3 quarters.
Penserra Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $44K in Q4 2021.
57 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.